Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-based therapy of hepatitis C.

Stéphane Chevaliez1, Jean-Michel Pawlotsky

  • 1French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hôpital Henri Mondor, Université Paris 12, Créteil, France.

Advanced Drug Delivery Reviews
|September 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dried Blood Spot: A Tool to Ensure Broad Access to Hepatitis D Screening, Diagnosis, and Treatment Monitoring.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.

The Lancet. Microbe·2026
Same author

Delta Describe, the French Collaborative Project: The Profile and Management of Hepatitis Delta Patients in Metropolitan France.

Viruses·2026
Same author

Prospective multicentre study of upper respiratory mucosal transcriptomics reveals two major endotypes of critically ill COVID-19 patients.

Communications medicine·2026
Same author

Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Hepatitis C virus elimination: So close, so far?

Antiviral research·2026
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

Interferon (IFN) therapy, combined with ribavirin, is key for treating chronic hepatitis C. Tailoring treatment based on early viral response improves outcomes and guides new drug development.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Interferon (IFN) discovery celebrated its 50th anniversary in 2007.
  • Recombinant IFN-alpha clinical trials for chronic hepatitis C began in 1986.
  • Current hepatitis C treatment relies on pegylated IFN-alpha and ribavirin.

Purpose of the Study:

  • Review IFN classification, production, signaling, and mechanisms.
  • Describe pegylated IFN-alpha and ribavirin's action.
  • Discuss current treatment guidelines and future drug developments.

Main Methods:

  • Literature review of interferon classification and function.
  • Analysis of hepatitis C virus treatment strategies.
  • Examination of early virological response in therapy.

Related Experiment Videos

Main Results:

  • IFNs exhibit antiviral and immunomodulatory properties.
  • Pegylated IFN-alpha and ribavirin combination is standard care.
  • Early virological response may guide treatment optimization.

Conclusions:

  • Understanding IFN mechanisms is crucial for hepatitis C management.
  • Personalized treatment schedules based on early response show promise.
  • Ongoing research focuses on novel hepatitis C therapeutics.